[go: up one dir, main page]

NO20062187L - Furan derivatives as EP4 receptor antagonists - Google Patents

Furan derivatives as EP4 receptor antagonists

Info

Publication number
NO20062187L
NO20062187L NO20062187A NO20062187A NO20062187L NO 20062187 L NO20062187 L NO 20062187L NO 20062187 A NO20062187 A NO 20062187A NO 20062187 A NO20062187 A NO 20062187A NO 20062187 L NO20062187 L NO 20062187L
Authority
NO
Norway
Prior art keywords
optionally substituted
group
alkyl
receptor antagonists
furan derivatives
Prior art date
Application number
NO20062187A
Other languages
Norwegian (no)
Inventor
Alexander William Oxford
Neil Victor Harris
Keith Alfred James Stuttle
David Edward Clark
Kenneth Lyle Clark
Robert Alexander Coleman
Gary Fenton
Jonathan Mark Sutton
George Hynd
Richard Jon Davis
Original Assignee
Asterand Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0324269.0A external-priority patent/GB0324269D0/en
Application filed by Asterand Uk Ltd filed Critical Asterand Uk Ltd
Publication of NO20062187L publication Critical patent/NO20062187L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives en forbindelse med formel (I) eller et salt, solvat eller kjemisk beskyttet derivat derav, der en av R2 og R5 er: (i) H eller en eventuelt substituert C1-4 alkyl gruppe; eller (ii) en eventuelt substituert C5-7 arylgruppe, og den andre av R2 og R5 er den andre gruppe; m og n kan være 0 eller 1 i det m + n = 1 eller 2, RN er H eller eventuelt substituert C1-4 alkyl, R3 er enten: (i) karboksy; (ii) en gruppe med formelen (II); (iii) en gruppe med formelen (III), der R eventuelt er substituert C1-7 alkyl, C5-20 aryl eller NRN3RN4 der RN3 og R N4 uavhengig er valgt blant eventuelt substituert C1-4 alkyl; eller (iv) tetrazol-5-yl.A compound of formula (I) or a salt, solvate or chemically protected derivative thereof is disclosed, wherein one of R 2 and R 5 is: (i) H or an optionally substituted C 1-4 alkyl group; or (ii) an optionally substituted C5-7 aryl group, the other of R2 and R5 being the second group; m and n may be 0 or 1 where m + n = 1 or 2, RN is H or optionally substituted C 1-4 alkyl, R 3 is either: (i) carboxy; (ii) a group of formula (II); (iii) a group of formula (III) wherein R is optionally substituted C 1-7 alkyl, C 5-20 aryl or NRN 3 RN 4 where RN 3 and R N 4 are independently selected from optionally substituted C 1-4 alkyl; or (iv) tetrazol-5-yl.

NO20062187A 2003-10-16 2006-05-15 Furan derivatives as EP4 receptor antagonists NO20062187L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0324269.0A GB0324269D0 (en) 2003-10-16 2003-10-16 EP4 receptor antagonists
US51220003P 2003-10-20 2003-10-20
PCT/GB2004/004392 WO2005037812A1 (en) 2003-10-16 2004-10-15 Furan derivatives as ep4 receptor antagonists

Publications (1)

Publication Number Publication Date
NO20062187L true NO20062187L (en) 2006-07-07

Family

ID=34466432

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062187A NO20062187L (en) 2003-10-16 2006-05-15 Furan derivatives as EP4 receptor antagonists

Country Status (3)

Country Link
KR (1) KR20060097028A (en)
DE (1) DE602004018527D1 (en)
NO (1) NO20062187L (en)

Also Published As

Publication number Publication date
KR20060097028A (en) 2006-09-13
DE602004018527D1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
NO20092770L (en) Novel aminopyrimidine derivatives as PLK1 inhibitors
ATE417841T1 (en) FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
NO20080717L (en) Oxime derivatives and process for their preparation
KR20050085991A (en) Compounds exhibiting thrombopoietin receptor agonism
AP1902A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
WO2004035576A3 (en) Pre-organized tricyclic integrase inhibitor compounds
TW200510326A (en) Heterocyclic compounds and thrombopoietin receptor activators
WO2008051533A3 (en) Benzimidazole compounds
TW200732329A (en) Aryl-isoxazolo-4-yl-oxadiazole derivatives
WO2008126732A1 (en) Fused bicyclic heteroaryl derivatives
NO331165B1 (en) Derivatives of dioxane-2-alkylcarbamates, processes for their preparation and use thereof for the preparation of medicaments
EP1364950A4 (en) PYRIDOPYRIMIDINE OR NAPHTHYRIDINE DERIVATIVE
ATE259376T1 (en) HETEROCYCLIC COMPOUNDS, THEIR INTERMEDIATE PRODUCTS AND ELASTASE INHIBITORS
MA27065A1 (en) COMPOUNDS INHIBITING THE RELEASE OF INFLAMMATORY CYTOKINES.
WO2003072576A3 (en) Oxazolidinone derivatives, processes for their preparation, and pharmaceutical compositions containing them
MY161992A (en) Novel tetrahydroisoquinoline derivative
HRP20060124A2 (en) Process for the preparation of n-amino substituted heterocyclic compounds
NO20033131L (en) Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible NO synthase
NO20062187L (en) Furan derivatives as EP4 receptor antagonists
NO20063111L (en) Process for the preparation of thiazole pyrimidines
MY139258A (en) Carbamoyl-type benzofuran derivatives
WO2002098853A3 (en) Inhibitors of cell proliferation, angiogenesis, fertility, and muscle contraction
TW200517394A (en) Method for stabilization of diarylvinylene compounds
DE60128329D1 (en) Pyrrolopyridazine CONNECTIONS
TNSN08521A1 (en) Phenylpentadienoyl derivatives and their use as par 1 antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application